Proteome Sciences is a London (UK) and Frankfurt (Germany) based SME with expertise in proteomics and biomarker research. We have discovered and patented a large number of novel protein biomarkers for diagnosis, prognosis and treatment of key human diseases including neurodegenerative disorders, cancer, stroke etc. and provide protein biomarker services to pharmaceutical and diagnostics companies. Our PS Biomarker Services for discovery and validation of biomarkers includes gel-based and gel-free separations linked to tandem mass spectrometry. We use proprietary isobaric tagging for higher throughput and better precision in biomarker discovery. We have also developed identical isotopic tags for rapid development of biomarker validation assays using isotope dilution mass spectrometry and Selected Reaction Monitoring (SRM). Such MS-based assays are rapid to develop compared to immunoassay and have potential for high rates of multiplexing. Proteome Sciences also provides analysis of post-translational modifications (PTM) and assays for such PTMs. We have wide experience across the life sciences sector working with many different human and animal sample types including blood plasma, CSF, solid tissues, cell culture material etc. As a reflection of the quality of our approach, the purpose built, state-of-the-art research facility in Frankfurt is certified to ISO 9001:2008.
Show more
Cobham, GB
Size (employees)
36 (est)+3%
Proteome Sciences is headquartered in Cobham, GB
Report incorrect company information

Proteome Sciences Office Locations

Proteome Sciences has an office in Cobham
Cobham, GB (HQ)
Downside Bridge Rd Covenham House
Show all (1)
Report incorrect company information

Proteome Sciences Financials and Metrics

Proteome Sciences Financials

Proteome Sciences's revenue was reported to be £2.74 m in FY, 2016 which is a 45.8% increase from the previous period.

Revenue (FY, 2016)

2.7 m

Revenue growth (FY, 2015 - FY, 2016), %


Gross profit (FY, 2016)

1.5 m

Gross profit margin (FY, 2016), %


Net income (FY, 2016)

(2.3 m)

EBITDA (FY, 2016)

(2.1 m)

EBIT (FY, 2016)

(2.7 m)

Market capitalization (31-Oct-2017)

9.8 m

Closing share price (31-Oct-2017)


Cash (31-Dec-2016)

2.9 m
Proteome Sciences's current market capitalization is £9.8 m.
GBPFY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016


266 k849.5 k1.3 m10 m1 m1.2 m2.1 m1.6 m1.9 m2.7 m

Revenue growth, %


Cost of goods sold

113 k225.9 k329 k105.1 k257.3 k385.5 k592.7 k605 k791 k1.2 m

Gross profit

153 k623.6 k976.7 k9.9 m763.9 k767.5 k1.5 m956 k1.1 m1.5 m
GBPFY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(5.3 m)(4.6 m)(4 m)4.6 m(4 m)(4.3 m)(3.1 m)(3.6 m)(2.7 m)(2.3 m)

Cash From Operating Activities

4.1 m(4.1 m)(3 m)4 m(5.2 m)(3.4 m)(2.8 m)(3.3 m)(2.4 m)(2 m)

Cash From Financing Activities

4.3 m3.7 m2.7 m6.1 m23.9 k2.6 m4.8 m2.3 m2.9 m

Net Change in Cash

196 k(469.7 k)(282.4 k)9.4 m(5.3 m)(3.3 m)(218.3 k)1.4 m(72 k)882 k
GBPY, 2016

Financial Leverage

-51.3 x
Show all financial metrics
Report incorrect company information